Industry supported symposia are scientific programs developed for educational purposes. All symposia are in compliance with Accreditation Council for Pharmacy Education (ACPE) criteria for planning and implementation. Each provide 1.5 contact hours of ACPE credit. Meals or snack items are provided at the start of each event. Room capacities at symposia are limited and entrance is granted on a first-come, first-served basis.

Sunday, April 21: 12:00-2:00 p.m.

Forging a New Age in Alzheimer’s Care: Early Recognition and Early Intervention

Alzheimer’s disease (AD) is a debilitating disorder that affects 5.4 million people in the US, and its incidence has increased over every decade studied. Despite AD’s prevalence and characterization within the medical literature, it is diagnosed in only 50% of affected individuals. Meanwhile over a tenth of those diagnosed with AD have their diagnoses changed at autopsy. Alongside these deficits in the diagnosis of AD, currently available treatments for the disorder are chiefly palliative in nature and do not slow the progression of the disease itself. With recent advances however, these deficits may be overcome as modern medical science forges a new age in Alzheimer’s care. This activity will provide participants with the latest data regarding Alzheimer’s evaluation and investigational disease-modifying agents.

Faculty

Melody Ryan, PharmD, MPH, BCPS, CGP (Activity Chair)
Associate Professor
University of Kentucky College of Pharmacy
Department of Neurology, UK College of Medicine
Neurology Clinical Pharmacy Specialist, VAMC
Lexington, KY

Larry Ereshefsky, PharmD, BCPP, FCCP
VP, Chief Scientific Officer
Principal Clinical Pharmacologist, Parexel International
Los Angeles, CA
Adjunct Professor of Pharmacology
University of Texas Health Science Center

Val J. Lowe, MD
Professor of Radiology
Mayo Clinic
Minneapolis, MN

Additional Information

Offered by

Creative Educational Concepts

Supported by

Monday, April 22: 4:30-6:00 p.m.

Advances in the Pharmacologic Treatment of Major Depressive Disorder

This Practicum-based educational program utilizes diverse adult learning principles to update learners on emerging therapies for patients with major depressive disorder (MDD). While sustained remission currently remains elusive to many patients with MDD, new antidepressant therapies with novel mechanisms of action offer promise in improving adherence and outcomes. Through presentations of data from recent clinical trials, case-based feedback, and roundtable discussion sessions, this lively Practicum will engage participants in applying leading evidence and strategies for helping patients with MDD achieve treatment goals.

Faculty

Steven Stoner, PharmD, BCPP (Chair)
Clinical Professor and Chair
Department of Pharmacy Practice and Administration
UMKC School of Pharmacy

Kelly Lee, Pharm D, BCPP
Assistant Professor of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences

Additional Information

Offered by

Supported by

Tuesday, April 23: 12:15-2:00 p.m.

Rethinking the Role of Long-Acting Injectable Antipsychotics

Patients with schizophrenia who are started on oral SGAs have shown poor medication adherence and continuation after discharge. Recognizing that over 90% of patients miss at least one dose of medication, and, on average, one third of all doses, clinicians over the years have turned to using long-acting injectable antipsychotic (“LAIA” or “depot”) therapy as a way to minimize nonadherence. This educational session will provide a comprehensive update on long-acting injectable (LAI) antipsychotic agents and their role in the treatment strategies for schizophrenia. Expert speakers will provide a detailed outline of all existing and pending agents and examine how they may optimally be used to improve adherence and patient care with a focus on place in therapy.

Faculty

Roger W. Sommi, PharmD, FCCP, BCPP (Activity Chair)
Professor of Pharmacy Practice and Psychiatry
University of Missouri - Kansas City Schools of Pharmacy and Medicine
Kansas City, MO

Beth Winans, PharmD, BCPP
Clinical Associate Professor
Division of Pharmacy Practice and Administration
UMKC School of Pharmacy
Kansas City, MO

Matthew Fuller, PharmD, BCPP, BCPS, FASHP
Clinical Pharmacy Specialist, Psychiatry
Louis Stokes Cleveland VAMC
Cleveland, OH

Additional Information

Offered by

Creative Educational Concepts

Supported by